Q3 2026 Cannara Biotech Inc Earnings Call Transcript
Key Points
- Gross cannabis revenue increased 16% year over year to $44.1 million, demonstrating strong sales growth.
- Cannara Biotech Inc (LOVFF) maintained a 4.4% national retail market share, positioning it as the eighth-largest licensed producer in Canada.
- The company expanded its distribution footprint to over 49,000 points, indicating strong market penetration.
- Operational capacity increased with the activation of two additional grow zones, raising annualized production capacity to over 58,000 kilograms.
- Cannara Biotech Inc (LOVFF) secured a long-term international supply agreement with Curaleaf, providing a pathway into international markets with a potential contract value of up to $21 million.
- Gross margin decreased slightly to 42% from 44% last year, primarily due to product mix changes.
- Free cash flow decreased to $1.3 million from $11.7 million last year, largely due to higher capital expenditures.
- Year-to-date operating income and net income were lower than the prior year due to higher non-cash share-based compensation and increased investments in sales and marketing.
- Market share in Quebec normalized to 12.9% from a previous high, indicating a slight dip in performance.
- Increased competitive pressure in the market, particularly in shelf space and marketing spend, poses challenges to maintaining growth momentum.
Good morning, everyone. Welcome to Cannara Biotech's third-quarter 2026 earnings webcast for the three months ended May 31, 2026. Today's presenter is Nicholas Sosiak, Chief Operating Officer and Interim Chief Financial Officer of Cannara Biotech.
(Operator Instructions) Please be advised that today's conference is being recorded.
Before we begin, please refer to slides 2 and 3 of the company's cautions regarding forward-looking statements, market and industry data, and non-GAAP and other financial measures.
I will now turn the call over to Nicholas Sosiak. Please go ahead, sir.
Good morning, everyone, and thank you for joining me to review Cannara's Q3 2026 results for the period ended May 31, 2026. The third quarter demonstrated the depth and resilience of our business.
Gross cannabis revenue increased 16% year over year to $44.1 million, total net revenue reached $31.8 million, and adjusted EBITDA increased 11% to $8.5
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
